ACI
CHRS icon

AMP Capital Investors’s Coherus Oncology CHRS Stock Holding History

AMP Capital Investors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,850
Closed -$350K – 1198
2020
Q1 		$350K Buy
+20,850
New +$385K ﹤0.01% 946

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AMP Capital Investors's CHRS Position: Q2 2020 in Review

AMP Capital Investors sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 20,850 shares — an estimated $350K sold.

AMP Capital Investors first reported a position in CHRS in Q1 2020 and held it in 1 quarter. The position peaked at $350K in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

  • AMP Capital Investors reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
  • AMP Capital Investors sold 20,850 Coherus Oncology shares in Q2 2020, an estimated $350K.
  • AMP Capital Investors first reported a position in Coherus Oncology in Q1 2020 and held it in 1 quarter.
  • AMP Capital Investors's Coherus Oncology position peaked at $350K in Q1 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on AMP Capital Investors's 13F filing for Q2 2020, filed 14 Aug 2020.